Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata.

@article{Talpur2009PhaseIR,
  title={Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata.},
  author={Rakhshandra Talpur and Jenny Vu and Roland L. Bassett and Victor K Stevens and Madeleine Duvic},
  journal={Journal of the American Academy of Dermatology},
  year={2009},
  volume={61 4},
  pages={592.e1-9}
}
BACKGROUND Alopecia areata, hair loss caused by perifollicular T-cell infiltrates, is refractory to therapy. Bexarotene, a retinoid X receptor is a selective retinoid, induces T-cell apoptosis. OBJECTIVE We sought to determine the safety, including the dose-limiting toxicities with adverse events, and efficacy, ie, response rate, of bexarotene in alopecia areata. METHODS We conducted a phase I/II randomized, half-head trial of 1% bexarotene gel applied twice daily for 6 months. RESULTS In… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…